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Abstract
Background: Cre recombinase is a common reagent used for the in vivo on/off switching of the
expression of target genes flanked by loxP  sites. In particular, recombinant TAT-Cre fusion
constructs purified from bacteria have been used to promote the cell uptake of the enzyme.
However, the recovery of active TAT-Cre remains a demanding process and its specific activity
varies significantly among batches, making difficult data comparison.
Results:  We noticed a strong correlation between recombinase activity and enzyme
monodispersity. The existence of such correlation enabled us to indirectly monitor the TAT-Cre
recombinase activity during the multi-step purification process by measuring its monodispersity, a
parameter detectable by means of a spectrofluorimetric assay that allows the calculation of the
Aggregation Index (AI) in an easy and rapid way. AI values were recorded after each purification
passage to identify the critical steps and to choose optimal alternatives for chromatographic
conditions, desalting procedures, and protocols for bacterial endotoxin removal. Furthermore, the
effect of metal ions and temperature on TAT-Cre aggregation and inactivation was characterized
in vitro. Finally, we optimized the enzyme delivery protocol in vivo by following the accumulation
tuning of the reporter protein β-catenin.
Conclusion: A rational purification protocol for TAT-Cre has been developed by choosing the
options that minimize the enzyme aggregation. Our data suggest that AI measurement should
support the optimization of any protocol aiming at the recovery of monodispersed protein.
Background
Cre recombinase from bacteriophage P1 is commonly
used to induce specific recombination of DNA sequences
between two LoxP recognition sites [1,2]. The technique is
well established for in vitro applications [3] and it is
increasingly used as a means to switch on/off genes in vivo
to obtain conditional mutants in both cultured cells and
model animals [4-6].
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The in vivo effectiveness depends on two parameters: a)
the preservation of the enzyme activity and b) its efficient
uptake into the host cells. Cre recombinase is stable in the
range 37-42°C and shows a low, but reproducible, perme-
ability through cell membranes that can be strongly
increased by the fusion to basic peptides like TAT, derived
from HIV-TAT protein [6-8]. Other peptides have been
proposed as fusion partners and were compared for their
effectiveness in inducing Cre-dependent recombination in
vivo [7,9]. Interestingly, all of them seem to reduce the
structural stability of Cre recombinase [9].
So far, no manufacturer provides such reagents and the
research groups use their self-produced material that
tends to vary significantly in terms of both yields and
recombinase activity among different purified batches.
We investigated the relationship existing between enzyme
activity and its structural stability to identify the chemio-
physical factors responsible for the loss of Cre recombi-
nase activity during the purification process. Their
contribution to protein misfolding was detected by a sim-
ple and fast spectrofluorimetric method that evaluates
protein aggregation [10]. Its reliability was validated by
comparison with conventional analyses such as gel filtra-
tion and dynamic light scattering (DLS) and used to
design an optimized purification protocol since TAT-Cre
aggregation correlates with, and is predictive of, its recom-
binase activity.
Results
Purification parameters affecting TAT-Cre activity
The loss of enzymatic activity is usually correlated to the
loss of native structure. Misfolded proteins tend to aggre-
gate and can either precipitate or form soluble complexes.
The identification of soluble aggregates is feasible by
means of biophysical techniques. Among these, fluori-
metric analysis [10,11] has the advantage of being fast and
simple, and we already showed that it correlates with size
exclusion chromatography [11]. In contrast to folded pro-
teins, protein aggregates are characterized by elevated
light scattering at 280 nm and low emission at 340 nm.
The ratio between the two values (aggregation index, AI)
can be used as an indicator of monodispersity, with high
values indicating large aggregates and low values mono-
dispersity.
We purified a His-tagged TAT-Cre construct expressed in
bacteria at either 4°C or 20°C according to the protocol
published by Peitz et al. [12] (Figure 1). In both cases the
protein obtained after affinity purification was almost
homogeneously pure. A significant amount of the TAT-
Cre purified at 20°C precipitated during dialysis in PBS
and 10% glycerol. Insoluble aggregates were removed by
centrifugation and the final yields of soluble TAT-Cre were
12 mg/L and 4 mg/L for purifications performed at 4°C
and 20°C, respectively.
The recombinase activity was tested checking the decrease
of β-catenin accumulation in endothelial cells. The pro-
tein accumulates in the extracellular matrix and its expres-
sion can be silenced by knocking out its DNA sequence
inserted between two LoxP sites. The read out is easily
revealed by immunofluorescence (IF) and quantified by
WB analysis using cell lysates (Figure 2).
Soluble TAT-Cre purified at 4°C had an AI value of 0.4,
indicative of monodispersity, and was active. As shown in
Figure 2, the amount of β-catenin in the cells, visualized
by both IF and WB, was strongly reduced after TAT-Cre
treatment. In contrast, when the same enzyme was puri-
fied at 20°C, its AI value was 10 and no significant recom-
binase activity was detectable (Figure 2). The separation of
the two TAT-Cre samples by gel filtration confirmed that
the enzyme purified at 4°C was a monomer, while the
sample purified at 20°C formed large aggregates (Figure
3), according to the estimations of the fluorimetric assay.
Therefore, the first conclusions were that TAT-Cre mono-
dispersity is a suitable parameter to infer protein recombi-
nase activity and that monodispersity evaluation by AI is
a reliable method that can substitute the time consuming
gel filtration chromatography.
Next we measured the Tm of the purified, active TAT-Cre.
The relative high value (52°C) indicates that, although
temperature control is a crucial factor to preserve TAT-Cre
recombinase monodispersity and activity, the contribu-
tion of other process parameters may be crucial during the
purification. We were also interested in simplifying the
original purification protocol (Figure 1) and, conse-
quently, decided to systematically measure the AI values
at every single purification step to identify passages critical
for preserving Cre recombinase activity.
First, the possibility of substituting the batch affinity chro-
matography with an FPLC-based alternative was evalu-
Purification protocols Figure 1
Purification protocols. Comparative flow-chart indicating 
steps and time requested in the original (left) and the alterna-
tive (right) protocol. The passages that have been tested for 
modifications are reported in red.
Lysis
Tartaric acid precipitation
Centrifugation
IMAC (manual)
Elution (batch)
Dialysis (2 steps)
Storage
Cell treatment
Lysis (sonication)
Endotoxin treatment
Centrifugation
IMAC (FPLC)
Elution (FPLC)
Desalting
Storage (buffers)
Cell treatment 
(endosome escape)
2 h
30 min
30 min
4 h
30 min
18 h
Tot: >25 h
2 h
30 min
1 h
30 min
30 min
1.5 h
Tot: 6 hBMC Biotechnology 2009, 9:80 http://www.biomedcentral.com/1472-6750/9/80
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ated. Both Qiagen and GE ready-made columns were
tested and the results did not show significant differences
in terms of AI values and recombinase activity when TAT-
Cre was purified following the two protocols and using
the different resins (Figure 2). However, the FPLC option
allowed for an automated and faster (90 min instead of
more than 4 h) purification. Furthermore, protein could
be more extensively washed and eluted in a smaller vol-
ume and thus at a higher concentration.
The initial success prompted us to evaluate, with the help
of the AI analysis, further protocol simplifications. How-
ever, EDTA (2 mM) addition in the buffer could not sub-
stitute the tartaric acid precipitation and the AI
significantly increased when a desalting column was used
for buffer exchange as an alternative to the time-consum-
ing, two-step dialysis. Both modifications resulted in puri-
fied TAT-Cre with very low enzymatic activity (data not
shown).
Endotoxin removal
Even though it was not possible to find reliable alterna-
tives to some time-consuming steps, the results confirmed
the direct correlation between AI-evaluated monodisper-
sity and recombinase activity. Therefore, AI analysis was
used to optimize the endotoxin removal step and the
composition of the storage buffers. Proteins purified from
bacteria are commonly contaminated with endotoxins
and such molecules are incompatible with several experi-
mental designs. We compared three methods for endo-
toxin removal from samples of purified TAT-Cre, one
based on two-phase partition [13], the second on ion-
exchange chromatography, whilst in the third case a com-
mercial affinity chromatography column has been used
[14]. In the first instance, AI indicated a dramatic aggrega-
tion increase and the in vivo assay confirmed the loss of
enzymatic activity. On the contrary, both chromato-
graphic protocols prevented the protein aggregation, TAT-
Cre remained fully active, and both the coagulation test
and the induction of the endotoxin-marker genes MIP2
and IK-Ba in primary macrophages indicated a significant
endotoxin concentration reduction in comparison to the
untreated samples (data not shown).
The addition of 50% glycerol was sufficient to preserve the
TAT-Cre activity for at least 6 months, although the addi-
tion of 50 mM trehalose was useful to stabilize enzyme
batches that underwent more thawing/freezing cycles.
In vitro effect of chemiophysical perturbations on TAT-Cre 
monodispersity and recombinase activity
Next we analyzed in vitro what chemio-physical factors
were relevant for TAT-Cre stability. Protein aggregation
was evaluated by both AI and DLS, an analytical tech-
nique routinely used for measuring protein monodisper-
sity/polydispersity [15]. The estimation of the protein
TAT-Cre monodispersity evaluation by gel filtration and  aggregation index (AI) Figure 3
TAT-Cre monodispersity evaluation by gel filtration 
and aggregation index (AI). Affinity purified TAT-Cre 
samples were assessed for their fluorimetric AI values and 
immediately processed by gel filtration.
In vivo recombinase activity of TAT-Cre with different level  of soluble aggregation Figure 2
In vivo recombinase activity of TAT-Cre with differ-
ent level of soluble aggregation. β-catenin was inserted 
between loxP sequences in endothelial cells and the effect of 
TAT-Cre recombinase addition (100 μg/mL) was analyzed 24 
h after treatment by immunofluorescence on cultured cells 
and by WB evaluation of the β-catenin content. The 
untreated control was compared with cells incubated with 
enzyme samples purified using different protocols and scor-
ing different AI values.
Control – untreated cells
GE column – Tat-Cre
4° C                 AI: 0.08
Qiagen column – Tat-Cre
4° C AI: 0.15
Qiagen slurry – Tat-Cre
4° C AI: 0.4
Qiagen slurry – Tat-Cre
20° C AI: 10BMC Biotechnology 2009, 9:80 http://www.biomedcentral.com/1472-6750/9/80
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aggregation complexity performed by AI and DLS were
always in good agreement (Tables 1 and 2).
Metal ions may leak from resins used for affinity chroma-
tography [16] and induce protein oxidation and conse-
quent misfolding. For such reason we have compared the
suitability of different commercially available columns
(Figure 2) and the direct effect of NiCl2 on TAT-Cre mon-
odispersity (Table 1). Traces of metal ions (0.1 mM of
NiCl2 in the presence of 50 μg/mL of purified enzyme)
were sufficient to induce the partial aggregation of the
enzyme. EDTA was added to chelate free ions but, even at
the highest concentrations compatible with affinity chro-
matography (5 mM), it was able to mitigate only partially
the destabilizing effect of metal ions. In contrast, 200 mM
solution of tartaric acid completely prevented the Ni ion-
dependent TAT-Cre aggregation and was still compatible
with affinity chromatography.
Temperature increase above 4°C resulted in TAT-Cre
aggregation during purification and an incubation step of
10 min at 30°C was sufficient to induce its aggregation
during two-phase partition in the presence of the deter-
gent (data not shown). However, we found that the Tm of
the purified enzyme was 52°C and that it was insensitive
to temperature in the range of 20°C-40°C (Table 2). Incu-
bation at 20°C for 4 h or at 40°C for 10 min did not mod-
ify the protein monodispersity, suggesting that co-factors
might be necessary for the TAT-Cre's structural destabili-
zation. Our data suggest that the presence of metal ions
could catalyze a temperature-sensitive aggregation process
that is inhibited by the addition of the tartaric acid
(Table 1).
Also sonication seems to be a critical factor triggering the
aggregation process, at both 4°C and 20°C (Table 2). Tre-
halose, a chemical additive used to stabilize protein struc-
ture [17], could only partially limit the sonication-
dependent aggregation process. In contrast, the addition
of metal ions induced a synergistic effect on the process of
TAT-Cre aggregation, whilst the scavenging activity of tar-
taric acid limited the TAT-Cre sonication-induced aggrega-
tion.
TAT-Cre cell-uptake and release from endosome
The in vivo enzymatic activity of Cre recombinase relies on
the efficiency of two processes, namely its uptake into the
cells and its release into the cytoplasm.
Different constructs have been proposed for promoting
the Cre recombinase uptake into the cells [9,12]. As an
alternative to the TAT-dependent uptake, a construct in
which Cre was fused to 6×His plus a nucleus leader signal
(HNC) was designed and described as being even more
efficient than TAT-Cre in vivo [9]. However, in our hands
no active enzyme was recovered using the purification
Table 1: TAT-Cre recombinase in vitro stability in the presence of metal ions
DLS
(RH in nm)
AI
(280em/340em nm)
Control 3.98 - monodispersed 0.02
1 mM NiCl2 at 4°C polydispersed 8.5
10 mM NiCl2 at 4°C polydispersed 9.2
1 mM NiCl2 at 20°C - precipitated
1 mM NiCl2 at 30°C - precipitated
0.1 mM NiCl2 at 4°C polydispersed 3.1
0.01 mM NiCl2 at 4°C 4.15 - monodispersed 0.4
1 mM NiCl2 + 5 mM EDTA polydispersed 3.3
1 mM NiCl2 + 10 mM EDTA polydispersed 2.2
1 mM NiCl2 + 200 mM TA 3.92 - monodispersed 0.02
Enzyme monodispersity was analyzed by dynamic light scattering (DLS) and fluorimetric aggregation index (AI). Purified recombinant protein 
samples (50 μg/mL) were incubated 30 min at different temperatures in the presence of increasing NiCl2 concentrations and of the chelators EDTA 
and tartaric acid (TA). DLS: the hydrodynamic radius (RH) of the molecules in solution is expressed in nm; the AI is the ratio between the light 
scattering at 280 nm and the emission at 340 nm. Experiments have been performed in triplicate.BMC Biotechnology 2009, 9:80 http://www.biomedcentral.com/1472-6750/9/80
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protocol described in the original paper. AI analyses indi-
cated that HNC formed soluble aggregates. In contrast,
when the same protocol optimized for purifying the TAT-
Cre construct was used, 3-5 mg/L of monodispersed HNC
recombinase were purified. Monodispersed HNC and
TAT-Cre were compared for their recombinase activity in
vivo by using the β-catenin assay, but the HNC construct
resulted by far less active of TAT-Cre (Figure 4).
Polypeptides fused to TAT sequence remain trapped in the
endosomes after cell-uptake by macropinocytosis [6,18]
and several strategies have been proposed for inducing
their leakage and protein accumulation into the cyto-
plasm. We confirmed that 100 mM chloroquine [18,19]
was effective in making TAT-Cre recombinase available
inside the cells (Figure 5). However, chloroquine cytotox-
icity [18] prevents its use in sensitive cell lines. Therefore,
sucrose [20] was used as an alternative, although it
showed lower efficiency even in optimized conditions
(Figure 5). Performing confocal microscopy using anti-
bodies against the Early Endosome Antigen1 (EEA1, red
signal) and Alexa488-labeled TAT-Cre (green signal), it
was possible to confirm [18] the rapid uptake (less than
10 min) of the enzyme trapped into the endosome vesi-
cles (Figure 6, yellow signal), and a substantial disappear-
ance of TAT-Cre-filled vesicles in the presence of
chloroquine treatment (Figure 6).
Discussion
The Cre recombinase-dependent inducible knock-out of
specific genes sided by LoxP sites is a methodology of con-
stantly increasing interest [21]. Although recently an
increasing effort has been devoted to improve the activity
control of the Cre recombinase [22-25], a simple and reli-
able methodology for optimizing the protein purification
is always profitable due to the fact that a major technical
drawback remains the unavailability of commercial
enzyme produced under standard conditions and the con-
sequent variable activity of the home-made batches.
We first discovered that the enzymatic activity loss corre-
lated with protein aggregation and that the AI was a relia-
ble analytical indicator for immediate estimation of the
Cre monodispersity after each single purification step. The
AI is simple and fast to determine, showed a good agree-
ment with other conventional analytical methods for pro-
tein aggregation such as gel filtration and DLS and, what
is more, gives a value that is useful to compare the effi-
ciency of different TAT-Cre purification batches and their
stability during storage. It became, therefore, straightfor-
Table 2: Effect of physical treatments on the stability of purified TAT-Cre recombinase
DLS
(RH in nm)
AI
(280em/340em nm)
Control 3.98 - monodispersed 0.02
30' at 20°C 3.77 - monodispersed 0.04
60' at 20°C 3.87 - monodispersed 0.04
4 h at 20°C 3.94 - monodispersed 0.06
30' at 30°C 4.01 - monodispersed 0.06
10' at 40°C 3.96 - monodispersed 0.06
Sonication at 4°C polydispersed 10
Sonication at 20°C polydispersed 14
Sonication at 4°C + Trehalose polydispersed 3.7
Sonication at 4°C + NiCl2 polydispersed 46.7
Sonication at 4°C + TA polydispersed 2.5
Sonication at 4°C + NiCl2 + TA polydispersed 4.7
The effect of increasing temperature, sonication, trehalose (50 mM), NiCl2 (1 mM), and tartaric acid (200 mM) on the enzyme monodispersity was 
analyzed by dynamic light scattering (DLS) and fluorimetric aggregation index (AI) using purified recombinant protein samples (50 μg/mL). DLS: the 
hydrodynamic radius (RH) of the molecules in solution is expressed in nm; the AI is the ratio between the light scattering at 280 nm and the 
emission at 340 nm. Experiments have been performed in triplicate.BMC Biotechnology 2009, 9:80 http://www.biomedcentral.com/1472-6750/9/80
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ward to predict the recombinase enzymatic activity at any
time without the need to wait for the morphological/
physiological readout of the treated cells. Furthermore, it
became also possible to verify what purification steps and
conservation conditions were deleterious for Cre native
structure and, consequently, for its activity. Metal ions
may be stripped out of the column [16] and we showed
that they have the major responsibility for the enzyme
aggregation. As a consequence, their inadequate removal
resulted in the activity loss. Tartaric acid did not interfere
with affinity purification even at concentrations of 200
mM and scavenged metal ions in an extremely more effi-
cient way than EDTA, a conventional chelator used in
buffers but tolerated at a maximal concentration of 5 mM
in ion metal affinity chromatography. Furthermore, mild
sonication conditions (see Methods) were adopted fol-
lowing the observation that such a treatment enhanced
Cre aggregation.
Although the monodispersity of TAT-Cre purified from
independent bacterial cultures could slightly vary, batches
with AI values below 0.2 had high and comparable activ-
ity, namely the β-catenin content in treated cells became
almost undetectable by WB 24 h after recombinase addi-
tion.
Once determined the optimal purification protocol and a
reliable method for protein aggregation analysis, it
became also feasible to compare the in vivo efficiency of
different, but all monodispersed, Cre recombinase con-
structs and to show that a combination of TAT-Cre and
chloroquine treatment assured the best recombinase
activity in vivo. Preliminary results indicate that monodis-
persed TAT-Cre is suitable for in vitro recombination as
well (data not shown).
Conclusion
In order to be effective for in vivo treatment, Cre recombi-
nase must be enzymatically active and efficiently translo-
cated into the nucleus. We first found out that aggregation
prevented the protein activity and we identified the factors
leading to protein aggregation followed by the optimiza-
tion of the protocols for TAT-Cre purification and cell
treatment. We expect that the described methodology
based on the use of the AI will be generally suitable for set-
ting purification protocols and improving their quality
evaluation and reproducibility. For its simplicity, it
should be particularly convenient for labs not equipped
with specialized biophysical instrumentation.
Methods
Cre recombinase purification
TAT-Cre was purified by modifying the original method
described by Peitz et al. [7,12]. Bacterial pellets were resus-
pended in lysis buffer (50 mM Na2HPO4, 5 mM Tris pH
7.8, 500 mM NaCl, 1 mM PMSF) and incubated with lys-
ozyme 1 mg/mL (Sigma) and DNase 100 μg/mL (Roche).
The samples were sonicated using a water bath Bioruptor
from Diagenode (30 s on/30 s off pulses, at low intensity
for 15 minutes) and tartaric acid was added at a final con-
centration of 1 M. After incubation (5 min), the samples
were centrifuged 45 min at 40000 rpm and filtered using
a 0.22 μm filter (Millipore) before their loading on a 5 mL
His-Trap HP column (GE Healthcare) or a Ni-NTA col-
umn (Quiagen) equilibrated in 50 mM Na2HPO4, 5 mM
Tris pH 7.8, 500 mM NaCl.
Proteins were eluted in 50 mM Na2HPO4, 5 mM Tris pH
7.8, 500 mM NaCl, 300 mM imidazole, dialyzed in 20
mM HEPES, pH 7.4, 50% glycerol, 500 mM NaCl, and
final samples were sterilized by filtration using Millex-GV
filters (Millipore).
Cre-Rec (HCN) was cultured according to the conditions
described by Lin et al. [9] and purified using the same pro-
tocol developed for TAT-Cre.
Comparison of the recombinase activity of the constructs  TAT-Cre and HNC Figure 4
Comparison of the recombinase activity of the con-
structs TAT-Cre and HNC. β-catenin expression was 
knocked-out by the recombinase activity of either TAT-Cre 
or HNC (both 100 μg/mL) in the presence of chloroquine (0-
100 μM).
Control
TAT-CRE 100μg/mL +
100 mM chloroquine
HNC-CRE 100μg/mL +
150 mM chloroquineBMC Biotechnology 2009, 9:80 http://www.biomedcentral.com/1472-6750/9/80
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Trehalose (50 mM) was tested as an alternative to glycerol
for storing of the purified Cre recombinase resuspended
in 20 mM HEPES pH7.4 and 600 mM NaCl.
Cell culture and Cre recombinase activity in vivo and in 
vitro
Cell Culture
β-catenin flox-endothelial cells were grown at 37°C in
DME, 20% FCS, 100 μg/mL heparin, 5 μg/mL EC growth
supplement (homemade from calf brain), 100 U/L peni-
cillin/streptomycin, 2 mM glutamine, and 1 mM Na-pyru-
vate in the presence of 5% CO2.
Cre recombinase activity
Endothelial cells cultured in serum-free DME were treated
with either TAT-Cre or HNC (0-150 μg/mL) for 1 hour
and then incubated 30 min in the presence of chloroquine
(0-100 μM) or sucrose (0-500 mM). Following a wash in
DME, cells were cultured in complete medium for 24
hours.
Immunofluorescence
80,000 cell/well were seeded on coverslips coated with 0.5
mL of gelatin solution using 24-well plates. The day after
slides were rinsed three times in PBS, fixed with 4% for-
maldehyde, and permeabilized by 5 min incubation in
PBS plus 0.5% Triton X-100. Cells were successively
washed three times, blocked with 2% BSA, and incubated
in the presence of anti-β-catenin monoclonal antibody
diluted 1:100 in PBS/2% BSA. Donkey-anti mouse-cy3
was used as a secondary antibody. After DAPI incubation
(3 min) the slides were mounted and cells assessed by flu-
orescence microscopy at the DAPI and cy3 channels.
Confocal microscopy
Cells seeded on coverslips were first incubated with TAT-
Cre labeled with Alexa488 in serum-free DME and then in
the presence of 100 μM chloroquine for 10-60 min. Slides
were rinsed, fixed and permeabilized with 0.1% saponin
in PBS before being incubated 60 min in the presence of
anti-EEA1 (Santa Cruz Biotechnol) diluted 1:150 in PBS
Effect of chloroquine and sucrose addition on the TAT-Cre release from endosomes Figure 5
Effect of chloroquine and sucrose addition on the TAT-Cre release from endosomes. The β-catenin expression 
silencing induced by 100 μg/mL TAT-Cre in the presence of increasing concentrations of chloroquine (0-100 μM) and sucrose 
(0-500 μM) was evaluated by immunofluorescence. Similarly, the Cre recombinase activity of increasing TAT-Cre concentra-
tions (0-100 μg/mL) was examined in the presence of 100 μM chloroquine.
TAT-Cre 100 μg/mL
+ Chloroquine
TAT-Cre 100 μg/mL
+ Sucrose
0 μM
50 μM
500 μM
10 μM
100 μM
0 μM
Chloroquine 100 μM
+ TAT-Cre
0 μg/mL
10 μg/mL
50 μg/mL
100 μg/mLBMC Biotechnology 2009, 9:80 http://www.biomedcentral.com/1472-6750/9/80
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containing 2% BSA and 0,05% saponin. Donkey-anti
mouse-cy3 was used as a secondary antibody. After DAPI
incubation (3 min) the slides were mounted and images
were acquired at 405-,488-, 633-nm laser lines using a
confocal microscope (SP2, Leica).
Immunoblot analysis
Confluent cells were washed with ice-cold PBS and
scraped in lysis buffer. Samples were separated by SDS
PAGE (12%), transferred to nitrocellulose membranes
(0.45 μM, Whatmann), and probed with anti-β-catenin
monoclonal antibodies (BD Biosciences) diluted 1:500 in
PBS containing 5% dry milk. The secondary antibody was
an anti-mouse HRP-conjugated (BIO-RAD) diluted
1:20000 in PBST. Detection was carried out by chemiolu-
minescence (ECL, GE Healthcare).
Evaluation of protein aggregation
Size Exclusion Chromatography (SEC)
The apparent mass of TAT-Cre batches showing different
level of aggregation was evaluated at 4°C using
HiLoad16/60 Superdex 200 and Superose 12 10/300 GL
columns coupled to ÄKTA Explorer (GE Healthcare). The
running buffer was 20 mM HEPES, pH 7.4, 600 mM NaCl,
and the protein molecular mass was estimated using a low
molecular weight calibration kit (GE Healthcare).
Dynamic Light Scattering (DLS)
The measurements were performed at 18°C by employing
a DynaPro 99 (Protein Solutions) instrument and using
the Dynamics 5.20.05 software for data evaluation (Pro-
tein Solutions).
Aggregation Index (AI). The aggregation index [10] of Cre
recombinase samples was evaluated after having recorded
the signal between 260 and 400 nm and calculated the
ratio between the value of scattered light at 280 nm and
the emission peak at 340 nm. The fluorescence measure-
ments were performed using an AB2 Luminescence Spec-
trometer (Aminco Bowman Series 2) equipped with SLM
4 software and a J-810 spectrofluorimeter (Jasco).
Determination of the protein melting temperature (Tm)
First far UV circular dichroism spectra of folded proteins
were acquired using a J-810 spectrofluorimeter (Jasco).
The wavelength corresponding to the maximal signal var-
iation with respect to the zero was chosen and the value of
molar ellipticity was followed while the temperature was
constantly increased from 20°C to 100°C. Tm was calcu-
lated as the intersection between the midpoint transition
line and the ellipticity curve obtained as a function of the
temperature.
In vitro TAT-Cre stability tests
Purified recombinant protein samples (50 μg/mL in 20
mM HEPES, 150 mM NaCl, 5% glycerol) were used at dif-
ferent temperatures and incubation times, as specifically
indicated in the Table legends. NiCl2 was used at concen-
trations between 0.01 and 10 mM, EDTA at 5-10 mM, tar-
taric acid at 200 mM, and trehalose at 50 mM. Samples
were sonicated at 4°C in a water bath (5 times × 20 sec at
medium intensity) using a Diagenode Bioruptor.
Endotoxin removal
Ion chromatography. Purified TAT-Cre was loaded onto a
MonoQ 4.6/100 PE (GE Healthcare) and eluted with a
linear gradient 150 mM - 1 M NaCl. Fractions containing
TAT-Cre were pooled and checked for endotoxin content
(see below).
TAT-Cre recombinase uptake: endosome transport and enzyme release Figure 6
TAT-Cre recombinase uptake: endosome transport and enzyme release. Confocal microscopy was used to demon-
strate the co-localization of GFP-labeled TAT-Cre recombinase (100 μg/mL) and the antibodies against the Early Endosome 
Antigen1 (EEA1). The concomitant addition of chloroquine (100 μM) resulted in the disappearance of Alexa488-containing 
endosomes. The cells were fixed 10 min after Cre treatment and the pictures correspond to DAPI only staining, DAPI + anti-
EEA1, and the same plus Alexa488-TAT-Cre in the absence or in the presence of choroquine, respectively.
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Affinity chromatography. Purified TAT-Cre was loaded
onto an Endotrap Blue 1/1 column (Profos) and recov-
ered according to the manufacturer's instructions.
Two-phase partition. Endotoxin removal from TAT-Cre
preparation by using two-phase partition in the presence
of Triton X-114 was performed following the protocol
described by Liu et al. [13].
The endotoxin concentration was estimated using the
LAL-Gel Clot Pyrogent Plus Kit from Cambrex. The in vivo
evaluation of effective endotoxin removal was performed
by quantifying the expression of the stress markers MIP2
and IK-Ba in primary macrophages.
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